CN114478617A - 一种辛伐铵盐中间体的制备方法 - Google Patents
一种辛伐铵盐中间体的制备方法 Download PDFInfo
- Publication number
- CN114478617A CN114478617A CN202210093767.8A CN202210093767A CN114478617A CN 114478617 A CN114478617 A CN 114478617A CN 202210093767 A CN202210093767 A CN 202210093767A CN 114478617 A CN114478617 A CN 114478617A
- Authority
- CN
- China
- Prior art keywords
- reaction
- formula
- compound
- imidazole
- formula iii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FFPDWNBTEIXJJF-OKDJMAGBSA-N (3r,5r)-7-[(1s,2s,6r,8s,8ar)-8-(2,2-dimethylbutanoyloxy)-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid;azane Chemical compound [NH4+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)C(C)(C)CC)C[C@@H](C)C=C21 FFPDWNBTEIXJJF-OKDJMAGBSA-N 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims abstract description 62
- 238000006243 chemical reaction Methods 0.000 claims abstract description 33
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 238000010791 quenching Methods 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 4
- 239000012295 chemical reaction liquid Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 abstract description 11
- 239000002904 solvent Substances 0.000 abstract description 9
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- JDIIGWSSTNUWGK-UHFFFAOYSA-N 1h-imidazol-3-ium;chloride Chemical compound [Cl-].[NH2+]1C=CN=C1 JDIIGWSSTNUWGK-UHFFFAOYSA-N 0.000 description 6
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 5
- 229960004844 lovastatin Drugs 0.000 description 5
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 5
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
- C07C2602/28—Hydrogenated naphthalenes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明涉及一种辛伐铵盐中间体Ⅲ的制备方法,包括下述步骤:将化合物Ⅱ、咪唑和叔丁基二甲基氯硅烷混合,反应得到化合物Ⅲ。本发明的制备方法优点:反应无溶剂从而使辅料可以回收,从而降低生产成本。
Description
技术领域
本发明属于药物合成领域,具体涉及一种辛伐铵盐中间体化合物的制备方法。
背景技术
辛伐他汀关键中间体辛伐铵盐是以洛伐他汀(化合物Ⅰ)为原料,首先与正丁胺进行酰胺化反应,得到化合物Ⅱ;再用叔丁基二甲基氯硅烷对化合物Ⅱ的羟基进行保护制备化合物Ⅲ,接着依次进行甲基化,脱硅保护和脱酰胺保护,最后用氨水反应制备辛伐铵盐。
现有技术由化合物Ⅱ制备化合物Ⅲ的方法中以DMF为溶剂进行反应,但反应结束后咪唑盐酸盐和未反应完的咪唑溶解在DMF中,由于DMF沸点高无法从咪唑和咪唑盐酸盐中去除,从而导致关键辅料咪唑无法回收使生产成本大大增加,另外回收DMF需要用精馏塔,操作成本及设备成本高。
现有由化合物II制备化合物Ⅲ的方法需以DMF为溶剂,反应结束后DMF和咪唑难以回收从而极大地提高了生产成本。
发明内容
针对现有技术中存在的咪唑难以回收的缺陷,本发明提供一种无需溶剂制备辛伐铵盐中间体方法。所述方法得到的反应液无溶剂因此咪唑可以回收,与现有技术在溶剂中反应的产率相当。我们发现,虽然咪唑熔点为90℃,式Ⅱ化合物40℃为黏稠状态,但两者40℃以上混合后所得混合物为糊状,所以过量的咪唑能作为此处的反应溶剂;当温度过低(如30℃),混合物的状态过于黏稠,会影响反应;温度过高(如100℃),式Ⅱ所示化合物产率和纯度都会降低。
为实现上述目的,本发明采用如下技术方案:
本发明设计出如下改进的合成方法:以化合物II、咪唑和TBSCL为原料,反应来制备目的产物化合物Ⅲ。化合物Ⅲ可按按以下过程继续反应得到辛伐他汀。
具体而言,本发明提供一种式Ⅲ所示辛伐铵盐中间体的制备方法,所述方法为:
式Ⅱ所示化合物、咪唑、叔丁基二甲基氯硅烷(TBSCL)混合后,在40~90℃(优选50~90℃)下反应1小时以上(反应完全,优选1-4小时,特别优选2小时),所得反应液经后处理,得到所述式Ⅲ所示辛伐铵盐中间体;
所述的式Ⅱ所示化合物、咪唑与叔丁基二甲基氯硅烷的物质的量之比为1:2~10:2~10(优选1:2.97~9:2.67,特别优选1:2.97:2.67)。
进一步,所述式Ⅱ所示化合物由式I所示化合物(洛伐他汀)与正丁胺反应后,浓缩除正丁胺得到。具体地,所述式Ⅱ所示化合物按如下方法制备:式I所示化合物与正丁胺于45-70℃(优选50℃)下反应至洛伐他汀残留在0.3%以下,所得混合物70℃下减压浓缩,得到所述式Ⅱ所示化合物;所述式I所示化合物与正丁胺的物质的量之比为1:3~5,转化率基本可达到100%,因此,可将式Ⅱ所示化合物视为纯品。
进一步,所述后处理为:向所述反应液中加正己烷,加甲醇淬灭反应,加水溶解,分层,取油层水洗(两次),减压浓缩,得到所述式Ⅲ所示辛伐铵盐中间体。
优选地,所述甲醇与所述式Ⅱ化合物的物质的量之比为0.6~1:1(优选0.7:1)。
与现有技术相比,本发明的有益效果在于:
本发明采用过量咪唑代替DMF作为反应溶剂,反应后咪唑可以回收,从而有效地降低了生产成本。
具体实施方式
以下通过实施例进一步阐述本发明。应理解,这些实施例仅用于举例说明目的,而不是对本发明的限制。本领域技术人员根据本发明构思对其作出的各种改变或调整,均应落入本发明的保护范围内。
在具体反应中,作为原料化合物I、化合物Ⅱ和化合物Ⅲ之间的比例可以从产品成本的经济角度考量,根据化学平衡原理进行适当的比例调整,这是本领域技术人员能够理解的。
试剂:本发明实施例中使用的反应物均为化学纯。
实施例1
(1)将20g的化合物I(0.0494mol)和20g正丁胺(0.2734mol)加入100ml三口瓶中,加热至50℃搅拌反应至HPLC监测洛伐他汀残留在0.3%以下。反应完毕后70℃减压浓缩回收去正丁胺至不再减重,得到化合物式Ⅱ所示化合物。
(2)向上述三口瓶内加入10g咪唑(0.1469mol)和20gTBSCL(0.1327mol)50℃反应2小时,反应毕加80g正己烷,1g甲醇淬灭反应,加入50g水溶解,分层,油层用100g*2水洗涤两次,油层减压浓缩除去溶剂得34.68g化合物Ⅲ。
实施例2
(1)将20g的化合物I(0.0494mol)和20g正丁胺(0.2734mol)加入100ml三口瓶中,加热至50℃搅拌反应至洛伐他汀残留在0.3%以下。反应完毕后70℃减压浓缩回收正丁胺。回收正丁胺毕,
(2)向上述三口瓶内加入30g咪唑(0.4407mol)和20gTBSCL(0.1327mol)50℃反应2小时,反应毕加80g正己烷,1g甲醇淬灭反应,加入50g水溶解,分层,油层用100g*2水洗涤两次,油层减压浓缩除去溶剂得34.66g化合物Ⅲ。
咪唑回收:将收集到的水层合并,加入5.11g氢氧化钠,搅拌升温至90℃,减压回收除水,然后加入45g乙酸乙酯(或其它溶剂例如二氯甲烷)溶解咪唑,过滤除去氯化钠,滤液降温至0℃,过滤,烘干即得类白色粉末固体25.75g,含量97.39%。
对比例1(现有工艺)
将20g的化合物I和20g正丁胺加入100ml三口瓶中,加热至50℃搅拌反应。反应完毕后70℃减压浓缩除去正丁胺。回收正丁胺毕,向反应瓶内加入33g DMF,10g咪唑和20gTBSCL反应4小时,反应毕加80g正己烷,1g甲醇淬灭反应,分层,下层用30g*2正己烷萃,,油层合并用150g*3水洗,油层减压浓缩除去溶剂得34.54g化合物Ⅲ。
实施例3(反应温度)
其他操作同实施例2,唯一的区别在于步骤(2)反应的温度为70℃。
实施例4(反应温度)
其他操作同实施例2,唯一的区别在于步骤(2)反应的温度为90℃。
表1化合物Ⅲ的收率及纯度
从表1中可以看出,采用本发明的方法化合物Ⅲ的收率和纯度均很高。
Claims (6)
2.如权利要求1所述的式Ⅲ所示辛伐铵盐中间体的制备方法,其特征在于:所述反应的温度为50~90℃。
3.如权利要求1所述的式Ⅲ所示辛伐铵盐中间体的制备方法,其特征在于:所述反应的时间为1-4小时。
4.如权利要求1所述的式Ⅲ所示辛伐铵盐中间体的制备方法,其特征在于:所述的式Ⅱ所示化合物、咪唑与叔丁基二甲基氯硅烷的物质的量之比为1:2~10:2~10。
5.如权利要求1所述的式Ⅲ所示辛伐铵盐中间体的制备方法,其特征在于所述后处理为:向所述反应液中加正己烷,加甲醇淬灭反应,加水溶解,分层,取油层水洗,减压浓缩,得到所述式Ⅲ所示辛伐铵盐中间体。
6.如权利要求1所述的式Ⅲ所示辛伐铵盐中间体的制备方法,其特征在于:所述甲醇与所述式Ⅱ化合物的物质的量之比为0.6~1:1。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210093767.8A CN114478617B (zh) | 2022-01-26 | 2022-01-26 | 一种辛伐铵盐中间体的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210093767.8A CN114478617B (zh) | 2022-01-26 | 2022-01-26 | 一种辛伐铵盐中间体的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114478617A true CN114478617A (zh) | 2022-05-13 |
CN114478617B CN114478617B (zh) | 2024-06-21 |
Family
ID=81476039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210093767.8A Active CN114478617B (zh) | 2022-01-26 | 2022-01-26 | 一种辛伐铵盐中间体的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114478617B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102532185A (zh) * | 2010-12-21 | 2012-07-04 | 北大方正集团有限公司 | 洛伐酰胺二硅醚、辛伐他汀二硅醚和辛伐他汀的制备方法 |
CN104803959A (zh) * | 2014-01-24 | 2015-07-29 | 上虞京新药业有限公司 | 辛伐他汀的制备方法 |
-
2022
- 2022-01-26 CN CN202210093767.8A patent/CN114478617B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102532185A (zh) * | 2010-12-21 | 2012-07-04 | 北大方正集团有限公司 | 洛伐酰胺二硅醚、辛伐他汀二硅醚和辛伐他汀的制备方法 |
CN104803959A (zh) * | 2014-01-24 | 2015-07-29 | 上虞京新药业有限公司 | 辛伐他汀的制备方法 |
Non-Patent Citations (1)
Title |
---|
ERICK L. BASTOS ET AL.: "Microwave-Assisted Protection of Phenols as tert-Butyldimethylsilyl (TBDMS) Ethers Under Solvent-Free Conditions", SYNTHETIC COMMUNICATIONS, vol. 35, pages 1501 - 1509 * |
Also Published As
Publication number | Publication date |
---|---|
CN114478617B (zh) | 2024-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101215235A (zh) | 一种受阻酚类抗氧剂的合成方法 | |
EP1770084A1 (en) | Method for producing (z)-1-phenyl-1-diethylaminocarbonyl-2-aminomethyl cyclopropane hydrochloride | |
CN109096122B (zh) | 制备亚精胺的方法 | |
CN110938012A (zh) | 利多卡因的制备方法 | |
CN113185459A (zh) | 一种硫酸羟氯喹及其制备方法 | |
CN114478617A (zh) | 一种辛伐铵盐中间体的制备方法 | |
CN101972642B (zh) | 固体碱催化剂及基于其合成3-氯-2-羟丙基-三甲基氯化铵的方法 | |
CN112341313B (zh) | 3,5-二氯苯甲醇及羧胺三唑中间体的制备方法 | |
CN114835661A (zh) | 一种a-乙酰基-r-丁内酯工业制备方法 | |
CN111072450B (zh) | 一种烯丙醇类衍生物的合成方法 | |
CN114031511A (zh) | 一种苄索氯铵的合成方法 | |
CN111269149B (zh) | 一种5-(3,3-二甲基胍基)-2-氧代戊酸的生产工艺 | |
CN109796360B (zh) | 一种3-氨基-2-萘甲酸类化合物的制备工艺 | |
CN110698381A (zh) | 一种一锅两相法合成n-(苄氧羰基)琥珀酰亚胺的方法 | |
CN109942516A (zh) | 化合物ra在制备布瓦西坦中间体手性丁内酯中的用途 | |
CN115385777B (zh) | 一种基于硼氢化钠还原生成的醇的纯化方法 | |
CN112358442B (zh) | 一种2-氟-5-甲酰氯吡啶的制备方法 | |
CN115490701B (zh) | 一种斑蝥素的合成方法 | |
CN114084889B (zh) | 一种制备三甲硅烷基胺的方法 | |
CN115947675B (zh) | 一种雷沙吉兰中间体及其制备方法和应用 | |
CN110172041B (zh) | 合成环嗪酮的新方法 | |
CN115385806B (zh) | 制备曲美布汀和马来酸曲美布汀的方法 | |
JP7454498B2 (ja) | サリチルアミド酢酸塩の製造方法 | |
CN110498764B (zh) | 一种琥珀酸多西拉敏的合成方法 | |
CN102093301B (zh) | 沙坦联苯四唑的溶剂热合成法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Country or region after: China Address after: 312369 No.31, Weisan Road, Shangyu economic and Technological Development Zone, Hangzhou Bay, Shaoxing City, Zhejiang Province Applicant after: Shaoxing Jingxin Pharmaceutical Co.,Ltd. Address before: 312369 No.31, Weisan Road, Shangyu economic and Technological Development Zone, Hangzhou Bay, Shaoxing City, Zhejiang Province Applicant before: SHANGYU JINGXIN PHARMACEUTICAL Co.,Ltd. Country or region before: China |
|
CB02 | Change of applicant information | ||
GR01 | Patent grant |